Adjuvant Endocrine Therapy for Breast Cancer During Perimenopause

被引：1

作者：

Noss, D. ^{[1
]}

Buchholz, S. ^{[1
]}

Ortmann, O. ^{[1
]}

机构：

[1] Univ Regensburg, Klin Frauenheilkunde & Geburtshilfe, D-93053 Regensburg, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2010年 / 70卷 / 02期

关键词：

perimenopause; breast cancer; endocrine therapy; menopausal status; PREMENOPAUSAL WOMEN; AROMATASE INHIBITORS; HORMONE; CHEMOTHERAPY; METAANALYSIS; TAMOXIFEN;

D O I：

10.1055/s-0029-1240825

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Adjuvant endocrine treatment plays an important role in the treatment of estrogen responsive breast cancer. The treatment options for premenopausal women differ from those for postmenopausal women. Aromatase inhibitors (AI) improve the outcomes in postmenopausal women, while AI can induce an increase in estrogen secretion and tumor growth in premenopausal women. The standard therapy during premenopause remains tamoxifen with or without ovarian suppression by GnRH analogues. Treatment of perimenopausal breast cancer patients can be more complicated, because it is often difficult to determine menopausal status.

引用

页码：112 / 116

页数：5

共 28 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database [J].

Anderson, WF ;

Chatterjee, N ;

Ershler, WB ;

Brawley, OW .

BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 (01) :27-36

[3] A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project [J].

Burger, H. G. ;

Hale, G. E. ;

Robertson, D. M. ;

Dennerstein, L. .

HUMAN REPRODUCTION UPDATE, 2007, 13 (06) :559-565

[4] Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: Cases and lessons [J].

Burstein, Harold J. ;

Mayer, Erica ;

Partridge, Ann H. ;

O'Kane, Holly ;

Litsas, Georgia ;

Come, Steven E. ;

Hudis, Clifford A. ;

Goldstein, Donald F. ;

Muss, Hyman B. ;

Winer, Eric P. ;

Garber, Judy E. .

CLINICAL BREAST CANCER, 2006, 7 (02) :158-161

[5]

Carlson RW, 2004, BREAST CANCER RES TR, V88, pS237

[6]

Celio L, 1999, ANTICANCER RES, V19, P2261

[7]

Clarke M, 1998, LANCET, V351, P1451

[8] Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98 [J].

Coates, Alan S. ;

Keshaviah, Aparna ;

Thuerlimann, Beat ;

Mouridsen, Henning ;

Mauriac, Louis ;

Forbes, John F. ;

Paridaens, Robert ;

Castiglione-Gertsch, Monica ;

Gelber, Richard D. ;

Colleoni, Marco ;

Lang, Istvan ;

Del Mastro, Lucia ;

Smith, Ian ;

Chirgwin, Jacquie ;

Nogaret, Jean-Marie ;

Pienkowski, Tadeusz ;

Wardley, Andrew ;

Jakobsen, Erik H. ;

Price, Karen N. ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :486-492

[9]

Coombes RC, 2007, LANCET, V369, P906

[10]

Cuzick J, 2007, LANCET, V369, P1711

← 1 2 3 →